PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|May 2, 2014
- Pharmaceutical Technology-05-02-2014
- Volume 38
- Issue 5
Aggregation System Improves Analysis of Sub-Visible Particles
Aggregation System Improves Analysis of Sub-Visible Particles
Shimadzu Scientific Instrument’s Aggregates Sizer Aggregation Analysis System, provides real-time quantitative evaluation of 100 nm to 10 μm subvisible particle (SVP) aggregates. By screening and identifying aggregation-prone proteins in early-stage drug development, manufacturers can save time and reduce costs. The Aggregates Sizer is capable of identifying SVP particles from invisible to visible in a single measurement in microsample quantities as small as 0.4 mL. It also enables quantitative evaluation of the concentration of those aggregates. In addition, the Aggregates Sizer can execute ongoing measurements in intervals as short as one second, allowing users to evaluate rates of change at intermediate stages during the manufacturing process. A batch cell (5 mL sample capacity) enables observation of aggregation processes as samples are mechanically stimulated.
Articles in this issue
over 12 years ago
Extractables and Leachables Testingover 12 years ago
Mass Spectrometer Enhances Performance in Protein Analysisover 12 years ago
Data Integrity in the Analytical Laboratoryover 12 years ago
Q&A with Tony Mitchell, Pharma Tech Industriesover 12 years ago
Linking Drug Shortages and Quality Metricsover 12 years ago
EU Steps Up Inspection Effortsover 12 years ago
Boosting New Antibiotic Drug Development in Europeover 12 years ago
Freeze Drying Protein FormulationsRelated to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.